Senate Democrats are considering changes to the excise tax and biosimilars measures of their drug pricing legislation, according to lobbyists who are tracking the bill, and they might add back a measure on insulin, though it’s not clear which one. The drug pricing legislation is part of Democrats’ evolving budget reconciliation bill that as of Wednesday (July 27) would also extend for three years higher-than-usual tax credits for exchange plan premiums. On Thursday and Friday, the Senate parliamentarian heard arguments...